On Monday, Shares of Pentair, (NYSE:PNR), lost -1.06% to $50.46.
Pentair plc, declared that it will pay a regular quarterly cash dividend of $0.32 per share on November 6, 2015 to shareholders of record at the close of business on October 23, 2015. Pentair had formerly declared on December 10, 2014 the approval by its Board of Directors of an annual cash dividend rate of $1.28 per share, payable in four equal quarterly installments in 2015.
Pentair paid dividends of $1.10 per share in 2014. Pentair has raised its dividend for 39 successive years.
Pentair plc operates as a diversified industrial manufacturing company in the United States, Europe, and internationally. The company operates through Valves & Controls, Technical Solutions, Flow & Filtration Solutions, and Water Quality Systems segments. It designs, manufactures, markets, and services valves, fittings, automation and controls, and actuators, in addition to provides engineering, design, inspection, maintenance, and repair services.
Shares of Nektar Therapeutics (NASDAQ:NKTR), declined -1.29% to $13.74, during its last trading session.
Nektar Therapeutics, declared positive preclinical results for NKTR-214, a CD122-biased cytokine designed to preferentially stimulate the production and maintenance of tumor-killing T cells which are found naturally in the body. CD122, which is also known as the Interleukin-2 receptor beta subunit, is a key signaling receptor that is known to improvement the proliferation of CD8-positive effector T cells, and these CD8-positive T cells comprise a key component of the tumor infiltrating lymphocytes that provide cell-mediated anti-tumor effects.1
Results were presented this past Friday at the Inaugural CRI-CIMT-EATI-AACR Immunotherapy Conference in New York. NKTR-214 shows efficacy in multiple preclinical models as a single agent. Combination regimens with NKTR-214 and either anti-CTLA4 or anti-PD-1 checkpoint inhibitor therapies resulted in durable anti-tumor immunotherapeutic effects, which persisted long after the termination of dosing.
Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline comprises drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology.
At the end of Monday’s trade, Shares of Plains All American Pipeline, L.P. (NYSE:PAA), gained 0.69% to $32.33. After trading began at $32.25 the stock was seen hitting $32.612 as a peak level and $32.05 as the lowest level. The stock ended up at $32.33. The daily volume was measured at 2,596,212 shares. The 52-week high of the share price is $59.75 and the 52-week low is $30.06. The company has a market cap of $12,857 million.
Presently the company Insiders own 1.2% of Plains All American Pipeline, L.P. Company shares. In the past six months, there is a change of 0.15% in the total insider ownership. Institutional Investors own 61.8% of Company shares. During last 3 month period, 2.44% of total institutional ownership has changed in the company shares.
Plains All American Pipeline, L.P., through with its auxiliaries, engages in the transportation, storage, terminalling, and marketing of crude oil, natural gas liquids (NGL), natural gas, and refined products in the United States and Canada. The company operates in three segments: Transportation, Facilities, and Supply and Logistics. The Transportation segment transports crude oil and NGL through pipelines, gathering systems, trucks, and barges.
Finally, Retrophin Inc (NASDAQ:RTRX), ended its last trade with -12.15% loss, and closed at $25.10.
Retrophin, declared that Dr. Alvin Shih, Executive Vice President and Head of Research and Development, will present at the Leerink Partners 4th Annual Rare Disease Roundtable in New York City on Wednesday, September 30, 2015 at 8:50 a.m. ET.
Retrophin, Inc., a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of serious, catastrophic, or rare diseases. Its product line comprises Cholbam, a cholic acid for the treatment of bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of peroxisomal disorders, such as Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea, or complications from reduced fat soluble vitamin absorption; Thiola, which is indicated for the prevention of cystine stone formation in patients with severe homozygous cystinuria with urinary cystine greater than 500 mg/day, who are resistant to treatment with conservative measures of high fluid intake, alkali and diet modification, or who have adverse reactions to d-penicillamine; and Chenodal, a synthetic oral form of chenodeoxycholic acid for radiolucent stones in well-opacifying gallbladders.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
